Please use this identifier to cite or link to this item:
|Title:||Low-dose 5-fluorouracil adjuvant in laser therapy for HPV lesions in immunosuppressed patients and cases of difficult control|
|Authors:||Speck, Neila Maria de Góis [UNIFESP]|
Ribalta, Julisa Chamorro Lascasas [UNIFESP]
Focchi, José [UNIFESP]
Kesselring, F. [UNIFESP]
Freitas, V. G.
Universidade Federal de São Paulo (UNIFESP)
Hosp AC Camargo Fund Antonio Prudente
|Publisher:||I R O G Canada, Inc|
|Citation:||European Journal Of Gynaecological Oncology. Montreal: I R O G Canada, Inc, v. 25, n. 5, p. 597-599, 2004.|
|Abstract:||The authors established a protocol for the use of 5-fluorouracil (5FU) adjuvant in lasertherapy for clinical and subclinical HPV infection in immunosuppressed patients, persistent lesions and as reinforcement treatment in cases of poor progress. Sixty-four patients were evaluated, of whom 26 were immunosuppressed, 34 presented persistent lesions and four received intravaginal reinforcement treatment with 2.5 g 5% 5FU every two weeks, or biweekly vulvar reinforcement after lasertherapy. On average, five 5FU courses were used, but in the immunossuppressed patients its use was maintained indefinitely. The rate of complete response was 66%, but the immunossuppressed patients showed less response (46.2%) when compared with the persistent lesion/reinforcement treatment group (78.9%). The responses were positive in the two groups when compared to that with no response. We deem the use of low-dose 5FU an excellent alternative in cases of difficult HPV progress, presenting a low cost and minimal side-effects.|
|Appears in Collections:||Artigo|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.